|Bid||3.6800 x 900|
|Ask||4.7200 x 1200|
|Day's Range||3.5900 - 3.7400|
|52 Week Range||1.4200 - 4.7900|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nymox Pharmaceutical Corporation (NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
It hasn't been the best quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shareholders, since the share price...
HASBROUCK HEIGHTS, N.J., April 21, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer. This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment. The new publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection Treatment of Grade Group 1 Prostate Cancer: Four Year Results”.
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries. Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.
The CEO of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is Paul Averback. This report will, first, examine the CEO...
HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) ...
HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
If you own shares in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) then it's worth thinking about how it contributes...
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Nymox Pharmaceutical Corporation (NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders. Dr. Paul Averback CEO of Nymox commented, "Our team has been working diligently for many years and these intellectual property extensions are some of the fruits of our labors. For our shareholders this effectively is a major increase in the conventionally recognized timeline of proprietary rights, and thus the market exclusivity of our products and long-term valuations if approved.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
I have a simple yet effective way to screen for potential stocks to buy. If a stock price has dropped significantly, I check the insider buying.Insiders are people who have access to confidential information about the company. It goes without saying that they probably have a much better idea of what is happening in the company than most analysts. They certainly know more about it than I do.Over the years, many insiders have used this information to gain an unfair advantage over uninformed investors. One of the regulations that the SEC has established to prevent this kind of activity is the requirement that an insider must publicly disclose when they have made a transaction in their stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBecause of this, we outsiders can profit. We can find out if the insiders are buying or selling.There are many reasons why an insider of a company may be motivated to sell their stock. They could need to raise money for things such as buying a house, installing a pool, or paying a college tuition. But an insider will only buy the stock for one reason -- they believe that the stock is undervalued and that it will trade at a higher price, where they can make money. * 7 A-Rated Stocks to Buy for the Rest of 2019 These companies are on my radar screen as potential stocks to buy due to the significant insider buying that has occurred recently. Stocks to Buy: Carnival (CCL)Carnival (NYSE:CCL) is the popular cruise ship company. It has worldwide operations but the headquarters are in Miami, Florida.CCL has lost over 10% of its value since its June 20 earnings release was a disappointment to investors. Since then, there has been some significant insider buying.Last week, the president and chief executive officer of Carnival, Arnold Donald, made some large purchases of the stock. He invested $1 million when he bought 22,050 shares around $45.31.Mr. Donald also made a similar size investment in December, when the markets made the significant move lower and CCL was trading around current levels. He must believe that the stock is a good value at these levels.Randall Weisenburger is a director of Carnival. He must also believe that the recent selloff is over because he just made a considerable personal investment as well. He just paid $46.50 for 20,000 shares. This is $930,000. Hooker Furniture (HOFT)Hooker Furniture (NASDAQ:HOFT) is a home furnishings and logistics company. That's a fancy way of saying that they make and sell furniture.The stock of HOFT has dropped over 50% in the past year. At this time last year it was trading around $48 per share. The most recent close was $21.32. In June the shares dropped from $27 to current levels due to disappointing earnings results. The company blamed it on tariffs and higher lumber costs. * 7 Retail Stocks to Buy That Are Down in 2019 Douglas Townsend is the co-president of the Home Meridian Segment of the company. He must believe that this selloff has come to an end. Mr. Townsend just invested over $100,000 when he bought 4,900 shares at $21.64. Nymox Pharmaceutical Corporation (NYMX)Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is a biopharmaceutical company that engages in research and development of products for the ageing population. This sounds like a great business to be in, but NYMX must being doing something wrong. Over the past year the share price has dropped by 60%.James Robinson is a director of Nymox. Mr. Robinson must be tired of watching the stock fall and thinks that this selloff is overdone. He invested $150,000 when he recently paid around $1.50 for 100,000 shares.No firms on Wall Street follow this company. Some investors may consider this to be a good thing because they believe that if they can get into it before it is "discovered" by the big players, they will be able to make significant profits. Kroger (KR)Kroger (NYSE:KR) operates various types of stores, including food and drug stores, multi-department stores, jewelry stores and convenience stores.Like many retailers, KR stock has had a rough time over the past year. Shares have lost about 30% of their value since their highs last September. Some blame this on a combination of tariff concerns and the Amazon (NASDAQ:AMZN) effect.Ronald Sargent is Kroger's lead director. He must believe that the recent selloff has created a great buying opportunity. He just invested $107,000 of his personal funds when he bought 5,000 shares at $21.49. * 10 Stocks That Should Be Every Young Investor's First Choice This is the first time an insider has purchased shares of KR in two years. Maybe this is because the Board of Directors just increased the dividend by 14%. Dave & Busters Entertainment (PLAY)Dave & Busters Entertainment (NASDAQ:PLAY) owns and operates entertainment and dinning venues. Its concept is to offer customers the opportunity to eat, drink and play in one location.Unfortunately for the shareholders of PLAY, they have not been as entertained as the short-sellers have. Since early May, the price of the stock has fallen by 30%. This includes the drop of 20% that occurred when the company missed earnings estimates in early June.Michael Griffith is a director of Dave & Busters. He apparently thinks that this recent weakness in the stock has created a buying opportunity. He just invested almost $200,000 of his own money when he purchased 5,000 shares at an average price of $39.31.Currently, 10 firms on Wall Street follow PLAY stock. They like it as well. The average rating is overweight and the average price target is $50. Greif (GEF)Greif (NYSE:GEF) produces industrial packaging products and services.In the past four months, the price of GEF stock has dropped from $42 to $34. This has been attributed by analysts to lower volumes of sales in some sectors and higher debt burdens. It could also be under pressure due to worries about tariffs.Peter Watson is the president and chief executive officer of Greif. He must believe that the selloff is over and that the stock will appreciate from here. Mr. Watson just paid $32.71 for 15,000 shares of GEF. That is a $500,000 investment. * 7 F-Rated Stocks to Sell for Summer Seven firms follow Greif. Opinion seems to be widely varied. There are three buy ratings, three sell ratings, and one hold rating.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 A-Rated Stocks to Buy for the Rest of 2019 * 7 Education Stocks to Buy for the Future of Academia * 5 Stocks to Buy as You Rebalance Your Portfolio The post 6 Stocks to Buy Based on Insider Buying appeared first on InvestorPlace.